Cambridge Healthtech Instituteの第2回年次会議
2023年3月7 - 8日、PST（米国太平洋標準時）
精密医療の次なるステップとして、「シックケア」から「ヘルスケア」へのシフトが必要です。Cambridge Healthtech Instituteの第2回「プレシジョンヘルス」年次会議では、プレシジョンヘルスを推進する主な利害関係者が集まり、個別化されたヘルス・ウェルネス向け予測、予防、早期発見に焦点を当てています。プレシジョンヘルスを推進する技術革新には、コミュニティ全体の遺伝子スクリーニング、疾患の早期発見とリスク管理、予防的健康対策、AI・デジタルヘルスツール、在宅診断・モニタリング、個別化されたライフスタイル、ウェルネスなどが含まれます。新興のプレシジョンヘルス技術に対する投資、規制、市場参入戦略について紹介します。
GENOME SEQUENCING FOR NEWBORN SCREENING AND RARE DISEASE DIAGNOSTICS
Starting Precision Medicine for Genetic Diseases at Birth: Medical Perspectives
Stephen F. Kingsmore, MD, President & CEO, Rady Children's Institute for Genomic Medicine
The confluence of three factors - the $100 genome, 8-hour diagnosis by genome sequencing, and impact of the orphan drug act - has made a founding promise of the human genome project finally feasible. It is to identify over 500 genetic diseases that have effective therapies at birth and commence treatment at or before symptom onset. We will share medical and pharmaceutical perspectives of world-wide efforts to introduce newborn screening by genome sequencing.
Starting Precision Medicine for Genetic Diseases at Birth: Pharmaceutical Perspectives
Thomas Defay, Deputy Head, Diagnostic Strategy and Development, Alexion Pharmaceuticals
The human genome project helped set in motion an era of innovation spanning technology, policy, and R&D, creating an opportunity to identify many genetic diseases with known treatment options at birth. I will share an industry perspective on world-wide efforts to introduce newborn screening by genome sequencing, discuss the impact this is predicted to have on 500+ treatable disorders, and implications for emerging gene targeted therapies.
The Impact of Clinical Whole Genome Sequencing in a Global Population of Patients with Suspected Rare Genetic Disease
Ryan J. Taft, PhD, Vice President, Scientific Research, Illumina
Of the more than 250M individuals worldwide estimated to have and rare and undiagnosed genetic disease, only a small fraction have access to appropriate molecular testing. Here we report on the iHope program, an international effort spanning 8 countries and 24 clinical sites to provide clinical whole genome sequencing (cWGS) free of charge to patients with limited means. An analysis of more than 1000 geographically and ancestrally diverse cases shows high diagnostic and clinical impact in both high and low- and middle-income geographies.
Sponsored Presentation (Opportunity Available)3:35 pm
Refreshment Break in the Exhibit Hall with Poster Viewing4:05 pm
PLENARY KEYNOTE SESSION: MULTI-CANCER EARLY DETECTION
Sponsored Presentation (Opportunity Available)4:50 pm
Evaluation and Implementation of Multi-Cancer Early Detection Tests
Larry Kessler, ScD, Professor, Health Systems and Population Health, University of Washington; Deputy Chair, MCED Consortium
Multi-cancer early detection promises to improve cancer diagnosis, treatment and patient care. However, introducing MCED technologies into clinical care requires evaluation and assessment of benefits and risks, potential outcomes, costs, and value. The multi-stakeholder expert panel will address how MCED will impact clinical care, outstanding challenges in evidence generation, test reimbursement, market adoption, and equitable patient access.
Philip E. Castle, PhD, Director, Division of Cancer Prevention, National Cancer Institute, National Institutes of Health
Close of Day5:45 pm
Registration and Morning Coffee7:30 am
30th ANNIVERSARY OF TRI-CON PLENARY KEYNOTE SESSION: DIAGNOSTICS INNOVATION AND INVESTMENT TRENDS
Failure: The Best Way to Learn
Mara G. Aspinall, Managing Director, BlueStone Venture Partners; Professor of Practice, Arizona State University; Advisor, The Rockefeller Foundation
The thought of failure creates fear. The reality of failure creates opportunity. We must embrace failure and all it can teach. As Arianna Huffington said: “Failure is not the opposite of success - it’s part of success.” We will discuss how to think differently about failing - how to motivate yourself and your teams.
Diagnostics Innovation and Investment Trends
Tom Miller, Founder & Managing Partner, GreyBird Ventures, LLC
Diagnostics investing experts will review what is hot and what is not in the field. Technological trends and white spaces will be identified, and entrepreneurs will be given best practices to maximize chances for successful financing. The panel will also provide guidance to founders to optimize operational success post-financing and what to do in the event of a stumble, the dreaded pivot, or in dealing with failure.
Bruce J. Tromberg, PhD, Director, National Institute of Biomedical Imaging and Bioengineering, National Institutes of Health; Lead, NIH’s Rapid Acceleration of Diagnostic Technologies (RADx Tech) Program
Transition to Sessions9:15 am
DIAGNOSTICS AND DIGITAL MEDICINE FOR PRECISION POPULATION HEALTH
Remembering Precision Health: Lessons from 30 Years of Mostly Unscalable Innovation through Tech, Government, and Thousands of Cancer Patients
Eric Dishman, CEO, DishStrong Innovation; Former Director, All of Us Research Program, National Institutes of Health
Since my own cancer diagnosis at age 19, I have been striving to create precision health for myself, thousands of cancer patients I have tried to help, and through my roles as a researcher-turned-executive leading health & life sciences at Intel Corporation and, more recently, at the National Institutes of Health. Even with the huge platforms and budgets of big tech and the federal government - and even doing innovation "right" according to all of the experts - the magic of precision health impacts has remained mostly small-scale, ephemeral, and difficult to repeat. I'll share "lessons learned" from those scaling failures, including 1) broadening the mission of precision health; 2) doing better workforce & workflow design from the start; 3) building a bigger ecosystem of fellow travelers; and 4) rethinking pay-for-quality.
Bringing Consumer Health to Precision Medicine
Jacqueline Shreibati, MD, Senior Clinical Lead, Devices & Services (Consumer Health), Google
Medical care is estimated to account for only 20 percent of the modifiable contributors to healthy outcomes for a population. The other 80 to 90 percent - the social determinants of health - are determined by our health behaviors, social and economic factors, and physical environment. In this session, we will review the evidence, challenges, and opportunities for the use of consumer digital health tools in precision medicine. We will explore the ways in which patients are increasingly empowered to use their data to shape their own health journey.
Digital Diagnostics for Population-Scale Screening
Noah Zimmerman, PhD, Vice President, Translational Science, Tempus
The emergence of digital diagnostics - algorithms built on top of routinely collected clinical data - have created a new paradigm to screen large populations of individuals and identify disease early, to help select effective therapies. But deploying a test at scale also introduces new challenges. We explore these issues through the lens of an AI-powered ECG device to identify risk of undiagnosed disease.
Coffee Break in the Exhibit Hall with Poster Viewing10:55 am
IMPLEMENTING GENOMIC MEDICINE: POPULATION GENOMIC SCREENING FOR PRECISION HEALTH
Implementation and Outcomes of Hereditary Cancer Risk Screening with a Brief Patient-Administered Digital Tool
Colleen Caleshu, ScM, CGC, Senior Director, Clinical Research, Genome Medical
Digital tools offer a scalable approach to hereditary cancer risk assessment and have the potential to efficiently identify individuals in need of genetic evaluation in a variety of clinical settings. The RISE Hereditary Cancer Risk Assessment Module (HCRA) is a brief patient-administered digital screening tool that has been clinically validated for this purpose and is based on national testing guidelines. Usability, yield, and other implementation outcomes will be discussed specific to deployment in several a variety of specialty and primary care clinical settings.
Hidden Benefits of Comprehensive Genomic Profiling: Expanding Definition of Clinical Utility in Advanced Solid Cancer Policy
Julie Kaylor, Director, Medical Affairs, Managed Care, Guardant Health
While health plan policy frameworks typically assess the net benefit of a service against the net cost of that service, there are many attributes currently unaccounted for which contribute to the benefit and efficiencies of comprehensive genomic profiling tests in advanced cancer patients. We will explore some in the form of value of clinical trial direction, relevant quality of life outcomes, low risk of downstream or off-label costs, and the economic impacts beyond cost of testing.
Value Proposition and Market Access for Genomic Medicine
Molly McGinniss, Senior Director, Population Genomics and Precision Medicine, Genome Medical
One of the many challenges to genomic medicine implementation is the ability to design, develop, and launch programs that map to the values of key stakeholder communities. Understanding how patients, payers, health systems, and clinical providers assess the benefits of genomic screening is critical to successful implementation. This session will explore how to gain institutional leadership support, align program goals according to desired outcomes and ROI metrics, and evaluate opportunities for improving access and engagement with underserved and diverse communities.
Session Break1:10 pm
Luncheon Presentation (Sponsorship Opportunity Available) or Enjoy Lunch on Your Own1:15 pm
Refreshment Break in the Exhibit Hall with Last Chance for Poster Viewing1:45 pm
Close of Conference2:25 pm